The Neurodegeneration Consortium

A transformational initiative to identify and develop novel
therapeutics for Alzheimer’s disease.


Baylor College of Medicine

The University of Texas - MD Anderson Cancer Center

Massachusetts Institute of Technology

About Us

Our Mission

Identify Therapies that
will Slow, Stop, or Reverse
the Progression of
Alzheimer’s Disease

Meet the Team

The NDC is a consortium uniting the best and the brightest leading scientists with a seasoned drug development team with a singular mission to defeat neurodegeneration.

William J. Ray, Ph.D.

Philip Jones, Ph.D.

Huda Y. Zoghbi, M.D.

Li-Huei Tsai, Ph.D.

Susan L. Lindquist, Ph.D.

Hugo Bellen

Joshua M. Shulman, M.D., Ph.D.

Juan Botas, Ph.D.

Ronald DePinho, M.D.

Giulio Draetta, M.D., Ph.D. Professor

Joanna Louisa Jankowsky, Ph.D.

Hui Zheng, Ph.D.

News & Insights

  • 2012
  • Oct
The Robert A. and Renee E. Belfer Family Foundation commits to philanthropic donation of $25 million to form the Neurodegeneration Consortium (NDC).

The multi-disciplinary team will include researchers from Baylor College of Medicine, the Massachusetts Institute of Technology and the University of Texas MD Andersons Cancer Center’s Institute for Applied Cancer Science (IACS).

The aim is to better understand the underlying biology of Alzheimer’s disease and translate this knowledge into therapeutic interventions that can effectively alleviate symptoms by delaying, reversing and/or eliminating the pathology of the disease.

The gift is contingent on consortium partners raising an additional $25 million by January 2016.

  • 2013
  • Aug
The Neurodegeneration Consortium receives $5 million toward matching commitment from the Huffington Foundation.
  • 2015
  • Aug
The Neurodegeneration Consortium receives $3 million from the Chapman Foundation.
  • 2015
  • Dec
Axxam SpA (Milan/Italy) and the Neurodegeneration Consortium (NDC) at the University of Texas MD Anderson Cancer Center collaborate on a novel approach to Alzheimer’s disease research

The aim of the collaboration is to identify and develop novel small molecule modulators of an undisclosed G-protein coupled receptor linked to Alzheimer’s disease.